MTMinoru Toyota

Minoru Toyota

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minoru Toyota has a total of 278 co-authors. Here are the top co-authors by number of shared publications:

  • Kohzoh Imai

    Division of Novel Therapy for Cancer, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    23 shared publications
  • Yasushi Sasaki

    Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University, Sapporo, Japan

    19 shared publications
  • Hiromu Suzuki

    Division of Molecular Biology, Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan

    18 shared publications
  • Hiromu Suzuki

    First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

    17 shared publications
  • Takashi Tokino

    Authors' Affiliations: 1Department of Biochemistry, 2First Department of Internal Medicine, 3Department of Public Health, and 4Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University; 5Akita Red Cross Hospital, Akita; 6GeneticLab Co. Ltd., Sapporo; 7Department of Pathology, Iwate Medical University, Morioka; and 8The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    15 shared publications
  • Yasuhisa Shinomura

    First Department of Internal Medicine, Sapporo Medical University School of Medicine, S1, W16, Chuo-Ku, Sapporo 060-8543, Japan

    14 shared publications

Latest Publications

  • DGK-gamma is involved in suppression of malignant melanoma cell invasion

    by Akiko Sato, Masahiro Kai, Hiromu Suzuki, Takahiro Nishizaka, Tokimasa Hida, Akihiro Yoneta, Toshiharu Yamashita, Minoru Toyota

  • Open Access

    Correction: Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma

    by Yuka Aoki, Masanori Nojima, Hiromu Suzuki, Hiroshi Yasui, Reo Maruyama, Eiichiro Yamamoto, Masami Ashida, Mitsuhiro Itagaki, Hideki Asaoku, Hiroshi Ikeda, et al.


  • Open Access

    Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma

    by Yuka Aoki, Masanori Nojima, Hiromu Suzuki, Hiroshi Yasui, Reo Maruyama, Eiichiro Yamamoto, Masami Ashida, Mitsuhiro Itagaki, Hideki Asaoku, Hiroshi Ikeda, et al.

    Background: The aim of this study was to clarify the role of global hypomethylation of repetitive elements in determining the genetic and clinical features of multiple myeloma (MM). Methods: We assessed global methylation levels using four repetitive elements (long interspersed nuclear element-1 (LINE-1), Alu Ya5, Alu Yb8, and Satellite-α) in clinical samples comprising 74 MM samples and 11 benign control samples (7 cases of monoclonal gammopathy of undetermined significance (MGUS) and 4 samples of normal plasma cells (NPC)). We also evaluated copy-number alterations using array-based comparative genomic hybridization, and performed methyl-CpG binding domain sequencing (MBD-seq). Results: Global levels of the repetitive-element methylation declined with the degree of malignancy of plasma cells (NPC>MGUS>MM), and there was a significant inverse correlation between the degree of genomic loss and the LINE-1 methylation levels. We identified 80 genomic loci as common breakpoints (CBPs) around commonly lost regions, which were significantly associated with increased LINE-1 densities. MBD-seq analysis revealed that average DNA-methylation levels at the CBP loci and relative methylation levels in regions with higher LINE-1 densities also declined during the development of MM. We confirmed that levels of methylation of the 5' untranslated region of respective LINE-1 loci correlated strongly with global LINE-1 methylation levels. Finally, there was a significant association between LINE-1 hypomethylation and poorer overall survival (hazard ratio 2.8, P = 0.015). Conclusion: Global hypomethylation of LINE-1 is associated with the progression of and poorer prognosis for MM, possibly due to frequent copy-number loss.


  • Genome-scale DNA methylation analysis in GI cancers

    by Yoshiyuki Watanabe, Yoshihito Yoshida, Ritsuko Oikawa, Masaki Hara, Hiroshi Kiyokawa, Yoshinori Sato, Sachiko Hirai, Hideo Suzuki, Takashi Tsuda, Hiroyuki Inaba, et al.

  • Open Access

    Interferon-α/β and Anti-Fibroblast Growth Factor Receptor 1 Monoclonal Antibody Suppress Hepatic Cancer Cells In Vitro and In Vivo

    by Shigeru Sasaki, Tadao Ishida, Minoru Toyota, Akinobu Ota, Hiromu Suzuki, Akinori Takaoka, Hiroshi Yasui, Hiroyuki Yamamoto, Hideyasu Takagi, Masahiro Maeda, et al.

    Hepatocellular carcinoma (HCC) is the most commonly occurring primary liver cancer and ranks as the fifth most frequently occurring cancer, overall, and the third leading cause of cancer deaths, worldwide. At present, effective therapeutic options available for HCC are limited; consequently, the prognosis for these patients is poor. Our aim in the present study was to identify a novel target for antibody therapy against HCC. We used Western blot and flow cytometric and immunocytochemical analyses to investigate the regulation of FGFR1 expression by interferon-α/β in several human hepatic cancer cell lines. In addition, we tested the efficacy of combined treatment with anti-FGFR1 monoclonal antibody and interferon-α/β in a murine xenograft model of human HCC. We found that interferon-α/β induces expression of FGFR1 in human HCC cell lines, and that an anti-FGFR1 monoclonal antibody (mAb) targeting of the induced FGFR1 can effectively inhibit growth and survival of HCC cells in vitro and in vivo. Moreover, the combination of interferon-α, anti-FGFR1 mAb and peripheral blood mononuclear cells (PBMCs) exerted a significant antitumor effect in vitro. Our results suggest that the combined use of an anti-FGFR1 antibody and interferon-α/β is a promising approach to the treatment of HCC.


  • Open Access

    Epigenetic Alteration of DNA in Mucosal Wash Fluid Predicts Invasiveness of Colorectal Tumors

    by Seiko Kamimae, Eiichiro Yamamoto, Hiro-O Yamano, Masanori Nojima, Hiromu Suzuki, Masami Ashida, Tomo Hatahira, Akiko Sato, Tomoaki Kimura, Kenjiro Yoshikawa, et al.

    Although conventional colonoscopy is considered the gold standard for detecting colorectal tumors, accurate staging is often difficult because advanced histology may be present in small colorectal lesions. We collected DNA present in mucosal wash fluid from patients undergoing colonoscopy and then assessed the methylation levels of four genes frequently methylated in colorectal cancers to detect invasive tumors. We found that methylation levels in wash fluid were significantly higher in patients with invasive than those with noninvasive tumors. Cytologic and K-ras mutation analyses suggested that mucosal wash fluid from invasive tumors contained greater numbers of tumor cells than wash fluid from noninvasive tumors. Among the four genes, levels of mir-34b/c methylation had the greatest correlation with the invasion and showed the largest area under the receiver operating characteristic curve (AUC = 0.796). Using cutoff points of mir-34b/c methylation determined by efficiency considerations, the sensitivity/specificity were 0.861/0.657 for the 13.0% (high sensitivity) and 0.765/0.833 for the 17.8% (well-balanced) cutoffs. In the validation test set, the AUC was also very high (0.915), the sensitivity/specificity were 0.870/0.875 for 13.0% and 0.565/0.958 for 17.8%. Using the diagnostic tree constructed by an objective algorithm, the diagnostic accuracy of the invasiveness of colorectal cancer was 91.3% for the training set and 85.1% for the test set. Our results suggest that analysis of the methylation of DNA in mucosal wash fluid may be a good molecular marker for predicting the invasiveness of colorectal tumors. Cancer Prev Res; 4(5); 674–83. ©2011 AACR.


  • Usefulness of DNA Methylation Analysis Using Gastric Washes as a Treatment Marker for Early Gastric Cancer

    by Yoshichika Oishi, Yoshiyuki Watanabe, Tetsuya Hiraishi, Ritsuko Oikawa, Tadateru Maehata, Hiromu Suzuki, Minoru Toyota, Fumio Itoh

  • IL-6, a Potential Inducer of DNA Hypermethylation and Malignant-Type Glycosylation in Ulcerative Colitis

    by Yuki I. Kawamura, Minoru Toyota, Teruki Hagiwara, Hiromu Suzuki, Motomi Yamazaki, Toshihiko Okada, Yutaka J. Kawamura, Fumio Konishi, Hideaki Yano, Yukio Saito, et al.

    • 1 September 2010
      • Vol. 37  (9) , 1650-3

    [Molecular mechanisms involved in epigenetic alterations in cancer].

    by Minoru Toyota, Hiromu Suzuki, Takahiro Nishizaka, Akiko Sato, Toshiharu Yamashita

    Epigenetic alterations such as DNA methylation and histone modification play a role in gene silencing in tumorigenesis. DNA methylation affects the expression of genes involved in cell cycle checkpoint, apoptosis, and DNA repair. Recently, epigenetic alterations are shown to play a role in silencing microRNA. Mutations of DNA methyltransferase and histone modification enzymes such as DNMT3A, UTX and EZH2 have been shown in various types of tumors. Genes involved in epigenetic regulation may be novel targets of cancer therapy in the near future.


    • 1 August 2010
      • Vol. 82  (8) , 693-701

    [Disease and epigenome analysis].

    by Minoru Toyota, Hiromu Suzuki, Masahiro Kai